In a significant milestone for India’s preventive healthcare ecosystem, Lord's Mark Industries Limited has become the first and only company in the country to receive a manufacturing licence for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD) for its Biomescan Analytics Platform. The development comes as India’s gut health market enters a high-growth phase, valued at USD 565.51 million in 2025 and projected to reach USD 1,619.56 million by 2034, expanding at a CAGR of 11.07%. With the market expected to grow substantially over the next three years, the licence positions Lord's Mark Industries Limited at the forefront of an emerging preventive healthcare opportunity, bringing gut microbiome science closer to mainstream wellness and early health management.